% | $
Quotes you view appear here for quick access.

Organovo Holdings, Inc. Message Board

  • before_its_news before_its_news Jan 26, 2013 6:42 PM Flag

    Organovo Inc.'s 3D Bioprinting Technology to be Discussed at Advanced Studies Laboratories (NASA Ames) on Feb. 1st

    Organovo Inc.'s 3D Bioprinting Technology to be Discussed at Advanced Studies Laboratories on Feb. 1st

    Keith Murphy, Chairman and CEO, along with Doctor Sharon Collins Presnell, CTO and EVP of Research & Development of Organovo, Inc. will present a seminar, "Organovo’s Bioprinting Platform: Enabling 3-D, architecturally correct, fully human tissue for drug discovery and transplantation" on Friday, February 1st at NASA Ames. An abstract and brief bios for Mr. Murphy and Dr. Presnell follow below. The seminar will be held in Building N239, Room B39 from 12:00-1:00pm. Refreshments will be provided and you are welcome to bring your lunch.

    This seminar is being co-hosted by the ASL and NASA Ames as part of the ASL and Ames Bio Talks and Syn Bio Talks Seminar series. Information about upcoming seminars and other events can be found here.

    Questions about this event can be directed to Peter Minogue.


    Creation of 3D tissues for both in vitro and in vivo use has historically relied on the combination of cells and either a hydrogel or polymeric biomaterial. Tissues that have been generated using biomaterials include skin, cartilage, bone, tubular structures, and tissue sheets of various compositions. As the field advances, alternative approaches to achieving three-dimensionality are emerging. Bioprinting involves the spatially-controlled deposition of cells into defined 3D structures that recapitulate compositional and architectural elements of native tissues without dependence on biomaterial scaffolding to achieve three-dimensionality. Organovo’s NovoGen MMX BioprinterTM deposits cylindrical or spherical cell aggregates layer-by-layer with spatial precision, yielding living tissues that are similar in architecture and function to native human tissues, and thus provides an alternative approach for the development of living human tissues for use in drug discovery and regenerative medicine.

    About the Speakers:

    Keith Murphy, Chairman and Chief Executive Officer, has more than 19 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. His 10 years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. Previous to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and worked to develop several other novel formulation and device products. He holds a BS in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.

    Sharon Collins Presnell, PhD, Chief Technology Officer and Executive Vice President of Research & Development, has more than 15 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Sharon joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research, and was responsible for the discovery and early development of Tengion’s Neo-Kidney AugmentTM technology, to which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a PhD in pathology from the Medical College of Virginia.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.81+0.10(+3.69%)May 27 4:01 PMEDT